Table 2.

Logistic regression model for the incidence of grade 3/4 febrile neutropenia in patients with ALL during continuation therapy that includes mercaptopurine according to the St Jude Total 13B protocol and ITPA genotype

	OR (95% CI)	P value
ITPA variant vs. ITPA wild type	2.98 (1.21–7.35)	0.018
Age
<1 Year vs. 1–10 years	0.57 (0.06–5.49)	0.063
More than 10 vs. 1–10 years	1.05 (0.39–2.84)	0.92
Race
Black vs. white	1.20 (0.41–3.50)	0.74
Other vs. white	0.52 (0.18–1.51)	0.23
Sex
Female vs. male	1.23 (0.56–2.73)	0.61
Treatment arm
High/standard risk vs. low risk	0.86 (0.34–2.17)	0.74

ALL, acute lymphoblastic leukemia; CI, confidence interval; ITPA, inosine triphosphate pyrophosphatase; OR, odds ratio.